ABSTRACT
INTRODUCTION Despite a two-fold increased risk, individuals of African ancestry have been significantly underrepresented in Alzheimer’s Disease (AD) genomics efforts.
METHODS GWAS of 2,903 AD cases and 6,265 cognitive controls of African ancestry. Within-dataset results were meta-analyzed, followed by gene-based and pathway analyses, and analysis of RNAseq and whole-genome sequencing data.
RESULTS A novel AD risk locus was identified in MPDZ on chromosome 9p23 (rs141610415, MAF=.002, P=3.68×10−9). Two additional novel common and nine novel rare loci approached genome-wide significance at P<9×10−7. Comparison of association and LD patterns between datasets with higher and lower degrees of African ancestry showed differential association patterns at chr12q23.2 (ASCL1), suggesting that the association is modulated by regional origin of local African ancestry.
DISCUSSION Increased sample sizes and sample sets from Africa covering as much African genetic diversity as possible will be critical to identify additional disease-associated loci and improve deconvolution of local genetic ancestry effects.
Competing Interest Statement
C.K is an advisor to Neuron D GmbH, Germany.
Funding Statement
This study was supported by NIH grants: U19AG074865 (MPV, CR, JLH, WB, BK, GB, AO, RA), R01AG072547 (MPV, CR, GB, JLH, RA), U01AG058654 (JLH, MPV, WSB, ERM, LAF, FR, MC, JMV), R01AG048927 (LAF), R01AG064614 (CR), U24AG056270 (RM, CR), P30AG066462 (CR), AG057659 (MPV), AG062943 (MPV).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Columbia University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced will be available online at https://www.niagads.org/
